Direct to confusion: Lessons learned from marketing brca testing

American Journal of Bioethics 8 (6):5 – 8 (2008)
Abstract Myriad Genetics holds a patent on testing for the hereditary breast and ovarian cancer genes, BRCA1 and BRCA2, and therefore has a forced monopoly on this critical genetic test. Myriad launched a Direct-to-Consumer (DTC) marketing campaign in the Northeast United States in September 2007 and plans to expand that campaign to Florida and Texas in 2008. The ethics of Myriad's patent, forced monopoly and DTC campaign will be reviewed, as well as the impact of this situation on patient access and care, physician liability, and the future of DTC campaigns for genetic testing.
Keywords No keywords specified (fix it)
Categories
Options
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
 
Download options
PhilPapers Archive


Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 5,679
External links
  • Through your library Configure

    Similar books and articles

    Analytics

    Monthly downloads

    Added to index

    2009-01-28

    Total downloads

    8 ( #123,092 of 549,087 )

    Recent downloads (6 months)

    1 ( #63,317 of 549,087 )

    How can I increase my downloads?


    My notes
    Sign in to use this feature


    Discussion
    Start a new thread
    Order:
    There  are no threads in this forum
    Nothing in this forum yet.

    Other forums